WELCOME TO P42MEDAI-powered platform for
safer drug design
Our approach
de novo designExploring new molecules
Our tools design novel molecules that were previously out of reach and allow us to work in the areas previously not addressed.
resource-lightHypothesis-driven design
Our automated scoring tools allow us to triage the resulting molecules and focus early on the most promising candidates.
cost-effectiveEvading the risks ahead
Our proprietary software allows us to avoid future costs by early prediction of pre-clinical and clinical stage failures.
BENEFITSDedicated to Providing Quality Laboratory Services
Novel drug classes
leveraging G-protein coupled receptors dimerization inhibition and their allosteric activation for pain management and therapies for neurodegenerative and autoimmune diseases.
End-to-end pipeline
for semi-autonomous design of our novel biotech drugs, followed by their synthesis, and experimental in-vitro validation.
Safety optimisation
variations of the drug will be optimised for safety and efficacy for genetically homogenous subpopulations with machine-learning tools to ensure their wide availability.
Lower costs
Our automated drug design pipeline will allow us to lower the costs enough to allow for equal and fair treatment of a greater number of patients during optimization, and make sure the groups previously excluded will be supplied with an effective therapeutic.
Multiple innovations orchestrated
to deliver best de novo therapeutics